CFO
CDLX icon

CVA Family Office’s Cardlytics CDLX Stock Holding History

CVA Family Office’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50
Closed -$4.11K – 1286
2024
Q2 		$4.11K Hold
50
– – ﹤0.01% 853
2024
Q1 		$7.25K Hold
50
– – ﹤0.01% 795
2023
Q4 		$4.61K Buy
+50
New +$5.08K ﹤0.01% 829
2023
Q3 		– Sell
-50
Closed -$3.16K – 346
2023
Q2 		$3.16K Hold
50
– – ﹤0.01% 851
2023
Q1 		$1.7K Hold
50
– – ﹤0.01% 869
2022
Q4 		$2.89K Hold
50
– – ﹤0.01% 790
2022
Q3 		$5K Hold
50
– – ﹤0.01% 714
2022
Q2 		$11K Hold
50
– – ﹤0.01% 625
2022
Q1 		$27K Hold
50
– – 0.01% 505
2021
Q4 		$33K Buy
+50
New +$38.2K 0.01% 432
2021
Q3 		– Sell
-50
Closed -$63K – 445
2021
Q2 		$63K Hold
50
– – 0.02% 326
2021
Q1 		$55K Hold
50
– – 0.02% 268
2020
Q4 		$71K Buy
+50
New +$53.3K 0.04% 158

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return
BCM
Brightlight Capital Management Westport, Connecticut $101M AUM 23.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CVA Family Office's CDLX Position: Q3 2024 in Review

CVA Family Office sold out of Cardlytics (CDLX) in Q3 2024, closing a stake of 50 shares — an estimated $4.11K sold.

CVA Family Office first reported a position in CDLX in Q4 2020 and held it in 13 quarters. The position peaked at $71K in Q4 2020. 111 funds tracked by Wall St. Rank hold CDLX as of Q3 2024.

  • CVA Family Office reported no remaining Cardlytics position as of Q3 2024 after selling out during the quarter.
  • CVA Family Office sold 50 Cardlytics shares in Q3 2024, an estimated $4.11K.
  • CVA Family Office first reported a position in Cardlytics in Q4 2020 and held it in 13 quarters.
  • CVA Family Office's Cardlytics position peaked at $71K in Q4 2020.
  • 111 funds tracked by Wall St. Rank held Cardlytics as of Q3 2024.

Based on CVA Family Office's 13F filing for Q3 2024, filed 10 Oct 2024.